142 related articles for article (PubMed ID: 3898142)
1. Intravesical chemotherapy for carcinoma of the bladder--duration of the treatment course.
Jakse G
Prog Clin Biol Res; 1985; 185B():69-78. PubMed ID: 3898142
[No Abstract] [Full Text] [Related]
2. Intravesical chemoprophylaxis of superficial transitional cell carcinoma of the bladder. When should the drug be given?
Bouffioux C
Prog Clin Biol Res; 1985; 185B():47-55. PubMed ID: 4034591
[No Abstract] [Full Text] [Related]
3. Intravesical chemotherapy for superficial bladder tumors category Ta/T1: who should be treated and how?
Kurth KH
Semin Urol Oncol; 1996 Feb; 14(1 Suppl 1):30-5. PubMed ID: 8727808
[TBL] [Abstract][Full Text] [Related]
4. Risk-adapted use of intravesical chemotherapy.
Lerner SP; Au JL
BJU Int; 2008 Nov; 102(9 Pt B):1247-53. PubMed ID: 19035889
[No Abstract] [Full Text] [Related]
5. Impact of intravesical chemotherapy on recurrence rate of recurrent superficial transitional cell carcinoma of the bladder: results of a meta-analysis.
Huncharek M; McGarry R; Kupelnick B
Anticancer Res; 2001; 21(1B):765-9. PubMed ID: 11299841
[TBL] [Abstract][Full Text] [Related]
6. What matters - early start or duration of chemotherapy instillation regimens or patient characteristics?
Kaasinen E
Eur Urol; 2008 May; 53(5):882-5; discussion 885-6. PubMed ID: 18262339
[No Abstract] [Full Text] [Related]
7. Intravesical chemotherapy in non-muscle-invasive bladder cancer: what schedule and duration of treatment?
Sylvester RJ
Eur Urol; 2007 Oct; 52(4):951-3; discussion 953-4. PubMed ID: 17374437
[No Abstract] [Full Text] [Related]
8. Apparent failure of current intravesical chemotherapy prophylaxis to influence the long-term course of superficial transitional cell carcinoma of the bladder.
Lamm DL; Riggs DR; Traynelis CL; Nseyo UO
J Urol; 1995 May; 153(5):1444-50. PubMed ID: 7714962
[TBL] [Abstract][Full Text] [Related]
9. [Intravesical therapy: Influence on superficial bladder cancer recurrence].
García Rodríguez J; Fernández Gómez JM; Escaf Barmadah S; González Alvarez RC; Jalón Monzón A; Martínez Gómez FJ; Sánchez Trilla A; Regadera Sejas J
Arch Esp Urol; 2007; 60(1):36-43. PubMed ID: 17408170
[TBL] [Abstract][Full Text] [Related]
10. Impact of intravesical chemotherapy versus BCG immunotherapy on recurrence of superficial transitional cell carcinoma of the bladder: metaanalytic reevaluation.
Huncharek M; Kupelnick B
Am J Clin Oncol; 2003 Aug; 26(4):402-7. PubMed ID: 12902895
[TBL] [Abstract][Full Text] [Related]
11. Intravesical chemotherapy--frequency of instillation.
Smith PH
Prog Clin Biol Res; 1985; 185B():57-68. PubMed ID: 3929271
[No Abstract] [Full Text] [Related]
12. Long-term intravesical adjuvant chemotherapy further reduces recurrence rate compared with short-term intravesical chemotherapy and short-term therapy with Bacillus Calmette-Guérin (BCG) in patients with non-muscle-invasive bladder carcinoma.
Friedrich MG; Pichlmeier U; Schwaibold H; Conrad S; Huland H
Eur Urol; 2007 Oct; 52(4):1123-29. PubMed ID: 17383080
[TBL] [Abstract][Full Text] [Related]
13. Intravesical chemotherapy.
Prout GR
Prog Clin Biol Res; 1984; 162B():125-50. PubMed ID: 6438639
[No Abstract] [Full Text] [Related]
14. Chemoprevention of superficial bladder cancer.
Kamat AM
Expert Rev Anticancer Ther; 2003 Dec; 3(6):799-808. PubMed ID: 14686702
[TBL] [Abstract][Full Text] [Related]
15. Is immediate postoperative intravesical chemotherapy beneficial in non-muscle- invasive bladder cancer?
Ayres BE; Crew JP;
BJU Int; 2010 Feb; 105 Suppl 2():14-7. PubMed ID: 20089093
[No Abstract] [Full Text] [Related]
16. Editorial comment on: Long-term intravesical adjuvant chemotherapy further reduces recurrence rate compared with short-term intravesical chemotherapy and short-term therapy with Bacillus Calmette-Guérin (BCG) in patients with non-muscle-invasive bladder cancer.
Evans CP
Eur Urol; 2007 Oct; 52(4):1129-30. PubMed ID: 17383082
[No Abstract] [Full Text] [Related]
17. Risk-adapted use of intravesical immunotherapy.
Braasch MR; Böhle A; O'Donnell MA
BJU Int; 2008 Nov; 102(9 Pt B):1254-64. PubMed ID: 19035890
[No Abstract] [Full Text] [Related]
18. Intravesical chemotherapy for maximum prophylaxis of new early phase superficial bladder carcinoma treated by transurethral resection: a combined analysis of trials by the Japanese Urological Cancer Research Group using smoothed hazard function.
Hinotsu S; Akaza H; Ohashi Y; Kotake T
Cancer; 1999 Nov; 86(9):1818-26. PubMed ID: 10547556
[TBL] [Abstract][Full Text] [Related]
19. Should all patients receive single chemotherapeutic agent instillation after bladder tumour resection?
Dobruch J; Herr H
BJU Int; 2009 Jul; 104(2):170-4. PubMed ID: 19493266
[No Abstract] [Full Text] [Related]
20. [Low-grade, low-stage transitional carcinoma of the bladder. Analysis of 147 cases].
Escudero Barrilero A; Gutiérrez Sanz-Gadea C; Hernández Fernández C; Mateos Torres A; Maganto Pavón E; Mayayo Dehesa T
Actas Urol Esp; 1985; 9(2):135-46. PubMed ID: 3925729
[No Abstract] [Full Text] [Related]
[Next] [New Search]
